Overview

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2038-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.
Phase:
PHASE2
Details
Lead Sponsor:
New Approaches to Neuroblastoma Therapy Consortium
Collaborators:
Children's Neuroblastoma Cancer Fund
Nationwide Children's Hospital
United Therapeutics
Treatments:
dinutuximab
Granulocyte-Macrophage Colony-Stimulating Factor
Irinotecan
sargramostim
Temozolomide